#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Transplant rejection Anti-myelin-associated glycoprotein associated polyneuropathy Transferrin decreased Chronic kidney disease Hyperphagia Acute leukaemia Arteriovenous malformation Non-Hodgkin's lymphoma unspecified histology indolent Retinopathy proliferative Transitional cell cancer of the renal pelvis and ureter Acute myeloid leukaemia refractory Alagille syndrome Diabetes insipidus Medulloblastoma recurrent Autoinflammation with infantile enterocolitis More trials…

    Learn about Rare Diseases

    Short-bowel syndrome – Basic Information Choroid melanoma – Treatment Methylmalonic acidaemia – Basic Information Indolent systemic mastocytosis – Diagnostics Mastocytosis – Treatment Ewing’s sarcoma recurrent – Treatment Small intestine leiomyosarcoma – Trials in Disease Fabry’s disease – Trials in Disease Brain stem glioma Propionic acidaemia – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Trimethoprim Lorazepam Sodium Acetate Trihydrate Nivolumab Colistin Sulfate Cart45Ra-Nkg2D Cells NIZUBAGLUSTAT Sucrose Tavapadon Doxribtimine Lactic Acid MALIC ACID Diclofenac Sodium Enlicitide Chloride Fludarabine Phosphate Ceftazidime Pancreas Powder Gskvx000000008866 Calcium Chloride Dihydrate Ulotaront More therapies…

    Learn about Your Condition

    Graft infection Dementia with Lewy bodies Metabolic surgery Endometrial cancer stage III Osteonecrosis of jaw Invasive breast carcinoma Retinal vein occlusion Mantle cell lymphoma Rheumatic disorder Raynaud's phenomenon Muscle hypertrophy Ischaemic skin ulcer Sinusitis bacterial IgA nephropathy Hypotransferrinaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Jean Perrin

Centre Jean Perrin

58 Rue Montalembert, Clermont Ferrand, 63000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil to Standard Treatment for Patients with Advanced Anal Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Anal squamous cell carcinoma
    Investigated Drugs:
    • Mitomycin
    • Capecitabine
    • Cisplatin
    France

  • Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Giredestrant
    • Abemaciclib
    • Fulvestrant
    Austria Belgium Finland France Germany Greece +7

  • Study Comparing Nivolumab to Placebo for Patients with High-Risk Invasive Bladder Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Nivolumab
    Austria Belgium Denmark France Germany Greece +7

  • Study Comparing [177Lu]LU-PSMA-I&T and Hormone Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Lutetium (177Lu) Zadavotide Guraxetan
    • Piflufolastat (18F)
    • Abiraterone Acetate
    France Italy Spain

  • Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    • Prostate cancer metastatic
    Investigated Drugs:
    • Enzalutamide
    • Pembrolizumab
    Austria Bulgaria Czechia France Germany Hungary +5

  • Study of Telisotuzumab Vedotin for Adults with Advanced Non-Squamous Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Telisotuzumab Vedotin
    France Germany Italy Romania Spain

  • Study of Pembrolizumab and Chemotherapy for Patients with Triple Negative Breast Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Anhydrous Cyclophosphamide
    • Filgrastim
    • Carboplatin
    France Germany Ireland Italy Poland Portugal +2

  • Study on the Safety and Effectiveness of Sacituzumab Govitecan for Patients with Triple Negative Metastatic Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Sacituzumab Govitecan
    Belgium France

  • Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-Hydroxy-2-Phenyl-1,2,3,4-Tetrahydronaphthalen-1-Yl]Phenyl]Piperidin-4-Yl]Methyl]Piperazin-1-Yl]-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione
    • Fulvestrant
    Austria Belgium Bulgaria Czechia Finland France +9

  • Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Capivasertib
    • Abemaciclib
    • Fulvestrant
    Belgium Denmark France Germany Italy Poland +2
Previous Page
1 … 16 17 18 19 20
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!